Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14269777 | 0.90 | SMN1; SMN2 (0.31) | SMN1; SMN2KDM4EALDH1A1GAAKMT2A | |
| SCHEMBL4878274 | 0.90 | TP53 (0.38) | SMN1; SMN2KDM4EALDH1A1GAAKMT2A | |
| SCHEMBL4867711 | 0.89 | CBX7 (0.33) | SMN1; SMN2KDM4E | |
| SCHEMBL4875214 | 0.88 | KMT2A (0.33) | SMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL4877163 | 0.88 | KCNH2 (0.39) | SMN1; SMN2TLR9TLR8TLR7ALDH1A1 | |
| SCHEMBL4877360 | 0.87 | KDM4E (0.37) | SMN1; SMN2KDM4E | |
| SCHEMBL4877570 | 0.87 | PTGS2 (0.32) | SMN1; SMN2KDM4EALDH1A1GAAKMT2A | |
| SCHEMBL4877238 | 0.85 | ALDH1A1 (0.33) | SMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL4876718 | 0.84 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1GAAKMT2A | |
| SCHEMBL4875238 | 0.84 | ALDH1A1 (0.39) | SMN1; SMN2ALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | SMN1; SMN2 1929/4885TLR9 985/4885TLR8 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.